NEWS
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s
Nuwellis, Inc. (Nasdaq: NUWE) has announced its first commercial sale of QUELIMMUNE™ therapy to Cincinnati Children's. QUELIMMUNE, developed by SeaStar Medical, is a novel treatment for pediatric patients with acute kidney injury (AKI) due to sepsis requiring kidney replacement therapy. The therapy, accessible under an FDA Humanitarian Device Exemption, has shown a 77% survival rate in early clinical data.
This milestone marks a significant advancement in pediatric critical care. Dr. Stuart Goldstein, Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital and Principal Investigator of the multi-center studies leading to FDA clearance, expressed enthusiasm for integrating QUELIMMUNE into their treatment arsenal. Nuwellis' exclusive U.S. license and distribution agreement with SeaStar Medical enables the commercialization of this innovative therapy.
This milestone marks a significant advancement in pediatric critical care. Dr. Stuart Goldstein, Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital and Principal Investigator of the multi-center studies leading to FDA clearance, expressed enthusiasm for integrating QUELIMMUNE into their treatment arsenal. Nuwellis' exclusive U.S. license and distribution agreement with SeaStar Medical enables the commercialization of this innovative therapy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7412Visitors
Follow